Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2025-12-16			5-day change	1st Jan Change
185,600.00 ^KRW	-1.17%		-0.80%	+2.95%

Dec. 10	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
Dec. 10	Celltrion, Inc. announces Annual dividend	CI

Press Releases

FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	Nov. 05	AQ
Celltrion Announces Launch Of AVTOZMA® (Tocilizumab-anoh) Intravenous Formulation In The United States	Oct. 14	AQ
FDA Approves Biocon's Denosumab Biosimilars	Sep. 30	AQ
Celltrion : announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients	Jun. 16	PU
Celltrion : Investor Presentation May & June 2025	May. 11	PU
Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	Apr. 29	AQ
Celltrion's STEQEYMA, now added to the Costco Member Prescription Program	Mar. 28	AQ
Celltrion Wins Costco Formulary Listing For Its Recently Launched Ustekinumab	Mar. 28	AQ
Celltrion Launches STEQEYMA® (ustekinumab-stba) In The United States	Mar. 26	AQ
U.S. FDA approves Celltrion's OMLYCLO as the first and only biosimilar with interchangeability designation referencing XOLAIR	Mar. 10	AQ
Celltrion : Investor Presentation March & April 2025	Mar. 06	PU
Celltrion : FY2024, 4Q24 Earning Release Celltrion Inc.	Feb. 25	PU
Celltrion Receives EC Approval for Avtozma, a Biosimilar to RoActemra	Feb. 24	AQ
Amgen And Celltrion Settle Denosumab BPCIA Case	Jan. 31	AQ
FDA Approves Celltrion's STEQEYMA (Ustekinumab-stba)	Jan. 09	AQ
BPCIA Lawsuit Against Accord's Proposed Prolia® / Xgeva® Biosimilar Filed By Amgen	Nov. 21	AQ
FDA Accepts ABLAs For Prolia® / Xgeva® Biosimilars From Organon And Teva	Nov. 07	AQ
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab, highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease	24-10-16	AQ
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab	24-10-16	AQ
Celltrion Wins Brazilian Federal Tender For Trastuzumab For Fifth Consecutive Year	24-09-20	AQ
Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents	24-08-16	AQ
Preliminary Injunction Issued Against Samsung Bioepis In Aflibercept BPCIA Litigation	24-06-20	AQ
European Biosimilar Regulatory Update	24-06-10	AQ
Amgen Files BPCIA Complaint Against Celltrion Regarding Denosumab	24-06-10	AQ
Celltrion - Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally	24-05-20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Press Releases

Filters